Get the Stockscreener App
1.2418
35.82%
-0.6982
Tscan Therapeutics Inc stock is traded at $1.2418, with a volume of 5.02M.
It is down -35.82% in the last 24 hours and down -41.00% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.94
Open:
$1.48
24h Volume:
5.02M
Relative Volume:
10.21
Market Cap:
$65.33M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.6937
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-45.39%
1M Performance:
-41.00%
6M Performance:
-22.19%
1Y Performance:
-74.85%
1-Day Range:
$1.10
$1.48
1-Week Range:
$1.10
$2.281
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.245 | 110.09M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.10 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.27 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.92 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.22 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com UK
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
Reversal indicators forming on TScan Therapeutics Inc. stockMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesRecession Risk & Low Risk Entry Point Tips - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackExit Point & Weekly Watchlist of Top Performers - newser.com
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Trading Recap & Daily Stock Trend Reports - newser.com
Technical signs of recovery in TScan Therapeutics Inc.Chart Signals & Stock Timing and Entry Methods - newser.com
Should you wait for a breakout in TScan Therapeutics Inc.Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.July 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Trend analysis for TScan Therapeutics Inc. this weekEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Is TScan Therapeutics Inc. still worth holding after the dipBull Run & Technical Pattern Recognition Alerts - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fearsWeekly Investment Summary & Fast Exit and Entry Strategy Plans - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Weekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Beat & Stock Portfolio Risk Control - newser.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):